Mandi

Mandi Inc. is a leading professional consumer healthcare company in China, dedicated to developing and providing comprehensive and long-term solutions for skin health and weight management. The company primarily focuses on the hair health segment within the broader skin health industry, where it has established a leadership position. Mandi's pipeline includes Clascoterone cream (Winlevi®), the world’s first and only topical androgen receptor inhibitor for acne vulgaris, which is currently undergoing Phase III clinical trials in China, with plans to submit a drug registration application in 2027. Additionally, the company is working on a long-acting GLP-1 receptor agonist, Semaglutide injection, for weight management, also in Phase III clinical trials in China, targeting submission of the drug registration application in the first half of 2026.